-
Capstone Therapeutics Corp. (NASDAQ:CAPS), Tempe, Ariz. Business: Dermatology, Pulmonary Capstone said it will cease development of its two compounds, AZX100 and TP508, to preserve cash and move towards winding down …
Published on 1/30/2012
-
Cellectis S.A. (Euronext:ALCLS), Paris, France Precision BioSciences Inc., Durham, N.C. Business: Genomics Precision said the U.S. Patent and Trademark Office (PTO) issued a non-final decision rejecting all Cellectis' …
Published on 1/30/2012
-
Fresenius SE(Xetra:FRE), Bad Homburg, Germany The Medicines Co.(NASDAQ:MDCO), Parsippany, N.J. Business: Cardiovascular The Medicines Co. and Fresenius' APP Pharmaceuticals Inc. generics unit resolved patent litigation …
Published on 1/30/2012
-
Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Neurology Merck will pay C$21.8-C$36.9 million ($21.4-$36.2 million) to resolve civil claims in Canada related to its promotion and marketing of …
Published on 1/30/2012
-
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass. Watson Pharmaceuticals Inc. (NYSE:WPI), Parsippany, N.J. Amphastar Pharmaceuticals Inc., Rancho Cucamonga, Calif. Business: Cardiovascular, Generics The U.S. …
Published on 1/30/2012
-
Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo Nordisk said it would establish a Type I diabetes R&D center in Seattle, Wash. The company said the center would combine basic …
Published on 1/30/2012
-
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Business: Endocrine/Metabolic, Hematology Alnylam said it will restructure and reduce headcount by 61 (33%) to about 115 to focus on development of its ALN-…
Published on 1/23/2012
-
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR), Burnaby, B.C. Business: Drug delivery Alnylam …
Published on 1/23/2012
-
Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Business: Cardiovascular Amarin filed a response with the U.S. Patent and Trademark Office (PTO) to a November non-final rejection letter for a patent application covering…
Published on 1/23/2012
-
Bioject Medical Technologies Inc. (OTCBB:BJCT), Tualatin, Ore. Business: Drug delivery Bioject retained financial advisor Snehal Patel to explore strategic alternatives, including the sale of the company. In its 3Q11 …
Published on 1/23/2012
-
Dendright Pty. Ltd., Brisbane, Australia Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Dendright partnered with the Janssen-Cilag Pty. Ltd. Australian unit of Johnson & Johnson and received a …
Published on 1/23/2012
-
Geron Corp. (NASDAQ:GERN), Menlo Park, Calif. Business: Gene/Cell therapy Geron disclosed in a Q&A session at the JPMorgan Healthcare Conference in San Francisco that it has hired Stifel Nicolaus to "find excellent …
Published on 1/23/2012
-
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Pharmaceuticals, Diagnostic Johnson & Johnson opened its Janssen Labs "innovation center" at its La Jolla-based West Coast Research Center in San Diego. The …
Published on 1/23/2012
-
NovaDel Pharma Inc. (OTCBB:NVDL), Bridgewater, N.J. Business: Genitourinary, Drug delivery NovaDel said it is continuing to seek strategic alternatives for the company, including raising capital or a sale of the company…
Published on 1/23/2012
-
Paragon Bioservices Inc., Baltimore, Md. Business: Infectious Contract research and manufacturing organization Paragon received a contract from the U.S. Department of Defense for the development and subsequent GMP …
Published on 1/23/2012
-
Quintiles Transnational Corp., Research Triangle Park, N.C. Business: Supply/Service CRO Quintiles launched a center of excellence in Dalian, China, to provide data management, biostatistics, postmarketing surveillance …
Published on 1/23/2012
-
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Pharmaceuticals Takeda said it will reduce headcount by about 2,800 by the end of 2015 and consolidate R&D sites following last year's acquisition of …
Published on 1/23/2012
-
University of Oxford, Oxford, U.K. Business: Cancer, Pharmacogenetics The University of Oxford spun out Oxford Cancer Biomarkers Ltd. (Oxford, U.K.) to discover cancer biomarkers and provide cancer consulting services. …
Published on 1/23/2012
-
Akebia Therapeutics Inc., Cincinnati, Ohio Business: Ophthalmic, Autoimmune Akebia spun out Aerpio Therapeutics Inc. (Cincinnati, Ohio) to focus on diabetic eye disease. The newco's lead compound is AKB-9778, a tyrosine…
Published on 1/16/2012
-
Albany Molecular Research Inc. (NASDAQ:AMRI), Albany, N.Y. Business: Supply/Service, Chemistry Contract research and manufacturing services company Albany Molecular Research said it is considering closing its facility …
Published on 1/16/2012
-
AlCana Technologies Inc., Vancouver, B.C. Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR), Burnaby, B.C. Business: Drug delivery The Supreme Court of British Columbia granted Tekmira's motion for a preliminary …
Published on 1/16/2012
-
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Pharmaceuticals AstraZeneca hired Briggs Morrison as EVP of global medicines development. He succeeds Anders Ekblom, who will lead the newly created Science …
Published on 1/16/2012
-
Bayer AG (Xetra:BAY), Leverkusen, Germany Business: Cardiovascular, Cancer Bayersaid by late summer it plans to open a life science incubator at its U.S. Innovation Center in San Francisco, Calif. The incubator, which …
Published on 1/16/2012
-
Cardio3 BioSciences S.A., Mont-Saint-Guibert, Belgium Business: Cardiovascular, Gene/Cell therapy Cardio3 received 3.1 million ($4 million) from the Walloon Region and the EU's seventh Framework Program (FP7). Cardio3 …
Published on 1/16/2012
-
Entelos Inc., San Mateo, Calif. Business: Computational chemistry/biology Private investor Clearlake Capital Group L.P. sponsored the recapitalization of Entelos and took a majority stake in the company. Existing …
Published on 1/16/2012